156 related articles for article (PubMed ID: 20956804)
1. Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis.
Hirai M; Kadowaki N; Kitawaki T; Fujita H; Takaori-Kondo A; Fukui R; Miyake K; Maeda T; Kamihira S; Miyachi Y; Uchiyama T
Blood; 2011 Jan; 117(2):500-9. PubMed ID: 20956804
[TBL] [Abstract][Full Text] [Related]
2. Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
Wissniowski TT; Meister S; Hahn EG; Kalden JR; Voll R; Ocker M
Int J Oncol; 2012 May; 40(5):1581-9. PubMed ID: 22266985
[TBL] [Abstract][Full Text] [Related]
3. Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells.
Dong H; Chen L; Chen X; Gu H; Gao G; Gao Y; Dong B
Leuk Lymphoma; 2009 Jun; 50(6):974-84. PubMed ID: 19391038
[TBL] [Abstract][Full Text] [Related]
4. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C
Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661
[TBL] [Abstract][Full Text] [Related]
5. Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways.
Fels DR; Ye J; Segan AT; Kridel SJ; Spiotto M; Olson M; Koong AC; Koumenis C
Cancer Res; 2008 Nov; 68(22):9323-30. PubMed ID: 19010906
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation.
Nencioni A; Schwarzenberg K; Brauer KM; Schmidt SM; Ballestrero A; Grünebach F; Brossart P
Blood; 2006 Jul; 108(2):551-8. PubMed ID: 16537813
[TBL] [Abstract][Full Text] [Related]
7. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.
Chauhan D; Singh AV; Brahmandam M; Carrasco R; Bandi M; Hideshima T; Bianchi G; Podar K; Tai YT; Mitsiades C; Raje N; Jaye DL; Kumar SK; Richardson P; Munshi N; Anderson KC
Cancer Cell; 2009 Oct; 16(4):309-23. PubMed ID: 19800576
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells.
Ichikawa HT; Conley T; Muchamuel T; Jiang J; Lee S; Owen T; Barnard J; Nevarez S; Goldman BI; Kirk CJ; Looney RJ; Anolik JH
Arthritis Rheum; 2012 Feb; 64(2):493-503. PubMed ID: 21905015
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.
Subklewe M; Sebelin-Wulf K; Beier C; Lietz A; Mathas S; Dörken B; Pezzutto A
Hum Immunol; 2007 Mar; 68(3):147-55. PubMed ID: 17349869
[TBL] [Abstract][Full Text] [Related]
10. UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes.
Kim YM; Brinkmann MM; Paquet ME; Ploegh HL
Nature; 2008 Mar; 452(7184):234-8. PubMed ID: 18305481
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells.
Nawrocki ST; Carew JS; Dunner K; Boise LH; Chiao PJ; Huang P; Abbruzzese JL; McConkey DJ
Cancer Res; 2005 Dec; 65(24):11510-9. PubMed ID: 16357160
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells.
Straube C; Wehner R; Wendisch M; Bornhäuser M; Bachmann M; Rieber EP; Schmitz M
Leukemia; 2007 Jul; 21(7):1464-71. PubMed ID: 17495970
[TBL] [Abstract][Full Text] [Related]
13. Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells.
Gu H; Chen X; Gao G; Dong H
Mol Cancer Ther; 2008 Aug; 7(8):2298-307. PubMed ID: 18723477
[TBL] [Abstract][Full Text] [Related]
14. The Chaperone UNC93B1 Regulates Toll-like Receptor Stability Independently of Endosomal TLR Transport.
Pelka K; Bertheloot D; Reimer E; Phulphagar K; Schmidt SV; Christ A; Stahl R; Watson N; Miyake K; Hacohen N; Haas A; Brinkmann MM; Marshak-Rothstein A; Meissner F; Latz E
Immunity; 2018 May; 48(5):911-922.e7. PubMed ID: 29768176
[TBL] [Abstract][Full Text] [Related]
15. HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells.
Xu Y; Hu Y; Shi B; Zhang X; Wang J; Zhang Z; Shen F; Zhang Q; Sun S; Yuan Z
Mol Immunol; 2009 Aug; 46(13):2640-6. PubMed ID: 19501403
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells.
Periyasamy-Thandavan S; Jackson WH; Samaddar JS; Erickson B; Barrett JR; Raney L; Gopal E; Ganapathy V; Hill WD; Bhalla KN; Schoenlein PV
Autophagy; 2010 Jan; 6(1):19-35. PubMed ID: 20110775
[TBL] [Abstract][Full Text] [Related]
17. The tyrosine kinase inhibitor dasatinib suppresses cytokine production by plasmacytoid dendritic cells by targeting endosomal transport of CpG DNA.
Fujita H; Kitawaki T; Sato T; Maeda T; Kamihira S; Takaori-Kondo A; Kadowaki N
Eur J Immunol; 2013 Jan; 43(1):93-103. PubMed ID: 23112129
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.
Fribley A; Zeng Q; Wang CY
Mol Cell Biol; 2004 Nov; 24(22):9695-704. PubMed ID: 15509775
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.
Berges C; Haberstock H; Fuchs D; Miltz M; Sadeghi M; Opelz G; Daniel V; Naujokat C
Immunology; 2008 Jun; 124(2):234-46. PubMed ID: 18217957
[TBL] [Abstract][Full Text] [Related]
20. Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis.
Kraus M; Malenke E; Gogel J; Müller H; Rückrich T; Overkleeft H; Ovaa H; Koscielniak E; Hartmann JT; Driessen C
Mol Cancer Ther; 2008 Jul; 7(7):1940-8. PubMed ID: 18645004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
